A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe-Reference-Cited by-同舟云学术

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe

Published:2020-01 Issue:1 Volume:72 Page:14-24
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Lazarus Jeffrey V.,Ekstedt Mattias^ORCID,Marchesini Giulio,Mullen Jillian,Novak Katja,Pericàs Juan M.,Roel Elena^ORCID,Romero-Gómez Manuel,Ratziu Vlad,Tacke Frank^ORCID,Cortez-Pinto Helena,Anstee Quentin M.^ORCID

Funder

EASL International Liver Foundation

Gilead Sciences Europe Ltd.

Allergan Pharmaceutical International Ltd.

Bristol-Myers-Squibb Company

Pfizer Inc.

Resoundant Inc.

University of Barcelona

Horizon 2020 Framework Program of the European Union

Publisher

Elsevier BV

Subject

Hepatology

Reference47 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;J Hepatol,2016

3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018

4. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

5. NAFLD incidence and remission: only a matter of weight gain and weight loss?;Marchesini;J Hepatol,2015

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future trends of the global burden of MASLD;Trends in Endocrinology & Metabolism;2024-08

2. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics;Clinics and Research in Hepatology and Gastroenterology;2024-08

3. The rise of multidisciplinary clinics in hepatology: A practical, how-to-guide, and review of the literature;Hepatology;2024-07-30

4. Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States;Frontiers in Medicine;2024-07-29

5. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis;Primary Care Diabetes;2024-06